UBS Says Impax 'Ahead Of Itself,' Downgrades To Sell By: Benzinga via Benzinga April 17, 2015 at 10:52 AM EDT UBS downgraded Impax Laboratories Inc (NASDAQ: IPXL) Thursday from Neutral to Sell and maintained a $36 price target. Analyst ... Read More >> Related Stocks: UBS Group Ag ADR